Pluto Bioinformatics

GSE103021: Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Bulk RNA sequencing

We report RNAseq gene expression data following ARS-1620 treatment and shKRAS expressing cells (NCI-H358). We also compare gene expression changes following treatment with ARS-1620 or trametinib in NCI-H358, LU65 (KRAS-G12C+), and A549 (KRAS-G12S+) cells. Additionally we report a time course (4, 24, 48hr) of ARS-1620 and trametinib treated NCI-H358 cells. SOURCE: Matthew Janes Wellspring Biosciences